ORMP
Closed
Oramed Pharmaceuticals Inc
2.1
-0.2 (-8.89%)
Last Update: 01 Jul 2025 23:00:00
Yesterday: 2.25
Day's Range: 2.105 - 2.2
Send
sign up or login to leave a comment!
When Written:
2.17
Oramed Pharmaceuticals Inc. is a biopharmaceutical company that specializes in the development of oral delivery solutions for drugs that are typically administered by injection. The company is based in Jerusalem, Israel, and was founded in 2006 by Dr. Miriam Kidron and Nadav Kidron.
Oramed's lead product candidate is ORMD-0801, an oral insulin capsule for the treatment of diabetes. The company has completed several clinical trials for ORMD-0801 and is currently conducting a Phase III trial.
In addition to ORMD-0801, Oramed is also developing oral delivery solutions for other drugs, including GLP-1 agonists for the treatment of diabetes and other metabolic disorders, and oral delivery solutions for vaccines.
Oramed has partnerships with several pharmaceutical companies, including Hefei Tianhui Incubator of Technologies Co. Ltd. in China and Premas Biotech in India.
Oramed is publicly traded on the NASDAQ stock exchange under the ticker symbol ORMP.
Note: This message is generated by artificial intelligence; it does not guarantee the accuracy of the information it contains and should not be considered as investment advice.
Oramed's lead product candidate is ORMD-0801, an oral insulin capsule for the treatment of diabetes. The company has completed several clinical trials for ORMD-0801 and is currently conducting a Phase III trial.
In addition to ORMD-0801, Oramed is also developing oral delivery solutions for other drugs, including GLP-1 agonists for the treatment of diabetes and other metabolic disorders, and oral delivery solutions for vaccines.
Oramed has partnerships with several pharmaceutical companies, including Hefei Tianhui Incubator of Technologies Co. Ltd. in China and Premas Biotech in India.
Oramed is publicly traded on the NASDAQ stock exchange under the ticker symbol ORMP.
Note: This message is generated by artificial intelligence; it does not guarantee the accuracy of the information it contains and should not be considered as investment advice.
(0)
(0)
Send
sign up or login to leave a comment!!








